Corindus Vascular Robotics of Natick said that the large Dutch conglomerate Royal Philips Electronics will help distribute its robot system designed for the treatment of patients with obstructed coronary arteries.
Under the agreement, Philips will sell the system in the United States, the companies said.
The financial details of the exclusive distribution agreement were not disclosed.
Recently approved by the Food and Drug Administration, the Corindus CorPath 200 is the first robotic-assisted system for the minimally invasive treatment of obstructed coronary arteries in patients with coronary artery disease, or CAD, the company said. The procedure used to clear arteries is known as percutaneous artery intervention, or PCI. The CorPath 200 System can be integrated with all major X-ray fluoroscopy systems including the Philips line of Allura X-ray equipment.
“Robotic-assisted interventional technologies have great potential to further improve current image-guided minimally invasive procedures, which is a fast growing market,” Gene Saragnese, chief executive of Imaging Systems at Philips Healthcare, said in a statement.
It is estimated that more than one million PCI procedures estimated will be performed in the United States during 2012, Saragnese said.
Headquartered in the Netherlands, Royal Philips Electronics employs about 122,00 people. It has several business lines, and its specialties include cardiac care, acute care and home health care, energy efficient lighting, and male shaving and oral health care products.
Philips and Corindus formed an alliance that was announced in 2011, and the distribution agreement covering the CorPath 200 is the latest step in that alliance, Corindus said. Philips owns a minority share in Corindus Vascular Robotics.